XL 5q31

Deletion Probe

Order Number
Package Size
100 µl


XL 5q31

This product has been replaced by XL Del(5)(q31). Order Number D-5085-100-OG

Clinical Details

The myelodysplastic syndromes and myeloproliferative disorders are associated with deregulated production of myeloid cells. According to WHO classification (2008) cytogenetic aberrations are observed in about 50 % of MDS cases. The most common aberrations are 5q-, 7/7q-, trisomy 8, del(20q), and inv(3) or t(3;3).

The 5q- syndrome is defined as a primary myelodysplastic syndrome (MDS) with del(5q) as the sole karyotypic abnormality and without excess of blasts. A commonly deleted region of the 5q- syndrome is approximately 1.5-megabases at 5q31-q32 and contains the EGR1 gene.

The del(5q) in AML, particularly secondary AML, invariably occurs together with other karyotypic abnormalities.

Clinical Applications

  • Myelodysplastic Syndrome (MDS)
  • Acute Myelogenous Leukemia (AML)


XL 5q31

XL 5q31 hybridized to bone marrow cells. One metaphase and one interphase are shown, displaying both a deletion in 5q31 (orange).

Expected Patterns

Expected Pattern 1

Normal Cell:
Two green (2G) and two orange (2O) signals.

Expected Pattern 2

Aberrant Cell (typical results):
Two green (2G) and one orange (1O) signal, indicating the deletion of the EGR1 at 5q31.


  • Horrigan et al (2000) Blood 95:2372-2377
  • Wei et al (2009) Proc Natl Acad Sci USA 106(31):12974-12979
  • Boultwood et al (2010) Blood 16:5803-5811


Order Now or Request Assistance

Contact Us »

Contact MetaSystems directly or find your local MetaSystems partner.